• 1
    Peterson LS, Mason T, Nelson AM, O'Fallon WM, Gabriel SE. Juvenile rheumatoid arthritis in Rochester, Minnesota 1960–1993: is the epidemiology changing? Arthritis Rheum 1996; 39: 138590.
  • 2
    Levinson JE, Wallace CA. Dismantling the pyramid. J Rheumatol 1992; 19 Suppl 33: 610.
  • 3
    Ruperto N, Levinson JE, Ravelli A, Shear ES, Tague BL, Murray K, et al. Longterm health outcomes and quality of life in American and Italian inception cohorts of patients with juvenile rheumatoid arthritis. I. Outcome status. J Rheumatol 1997; 24: 94551.
  • 4
    Giannini EH, Brewer EJ, Kuzmina N, Shaikov A, Maximov A, Vorontsov I, et al. Methotrexate in resistant juvenile rheumatoid arthritis: results of the U.S.A.-U.S.S.R. double-blind, placebo-controlled trial. N Engl J Med 1992; 326: 10439.
  • 5
    Wallace CA, Sherry DD. Preliminary report of higher dose methotrexate treatment in juvenile rheumatoid arthritis. J Rheumatol 1992; 19: 16047.
  • 6
    Lovell DJ, Giannini EH, Reiff A, Cawkwell D, Silverman ED, Nocton JJ, et al. Etanercept in children with polyarticular juvenile rheumatoid arthritis. N Engl J Med 2000; 342: 7639.
  • 7
    Petty RE, Southwood TR, Baum J, Bhettay E, Glass DN, Manners P, et al. Revision of the proposed classification criteria for juvenile idiopathic arthritides: Durban, 1997. J Rheumatol 1998; 25: 19914.
  • 8
    Ansell BM. Juvenile rheumatoid arthritis (rheumatoid factor positive polyarthritis). In: MaddisonPJ, IsenbergDA, WooP, GlassDN, editors. Oxford texbook of rheumatology. 2nd ed. Oxford (UK): Oxford University Press; 1998. p. 10316.
  • 9
    Whiting-O'Keefe QE, Fye KH, Sack KD. Methotrexate and histologic hepatic abnormalities: a meta-analysis. Am J Med 1991; 90: 7116.
  • 10
    Burgos-Vargas R, Pacheco-Tena C, Vazquez-Mellado J. Juvenile-onset spondyloarthropathies. Rheum Dis Clin North Am 1997; 23: 56998.
  • 11
    Giannini EH, Ruperto N, Ravelli A, Lovell DJ, Felson DT, Martini A. Preliminary definition of improvement in juvenile arthritis. Arthritis Rheum 1997; 40: 12029.
  • 12
    Ruperto N, Ravelli A, Falcini F, Lepore L, De Sanctis R, Zulian F, et al. Performance of the preliminary definition of improvement in juvenile chronic arthritis patients treated with methotrexate. Ann Rheum Dis 1998; 57: 3841.
  • 13
    Kremer JM, Alarcón GS, Lightfoot RW Jr, Willkens RF, Furst DE, Williams HJ, et al. Methotrexate for rheumatoid arthritis: suggested guidelines for monitoring liver toxicity. Arthritis Rheum 1994; 37: 31628.
  • 14
    Ruperto N, Martini A, for the Pediatric Rheumatology International Trials Organization (PRINTO). Use of unlabelled and off licence drugs in children: a European paediatric rule is needed to protect children. BMJ 2000; 320: 12101.
  • 15
    Albornoz MA. ACR formally adopts improvement criteria for juvenile arthritis (ACR pediatric 30). ACR News 2002; 21: 3.
  • 16
    Ravelli A, Viola S, Migliavacca D, Ruperto N, Pistorio A, Martini A. The extended oligoarticular subtype is the best predictor of methotrexate efficacy in juvenile idiopathic arthritis. J Pediatr 1999; 135: 31620.
  • 17
    Cassidy JT, Levinson JE, Bass JC, Baum J, Brewer EJ, Fink CW, et al. A study of classification criteria for a diagnosis of juvenile rheumatoid arthritis. Arthritis Rheum 1986; 29: 27481.
  • 18
    Ruperto N, Giannini EH. Redundancy of conventional articular response variables used in juvenile chronic arthritis clinical trials. Ann Rheum Dis 1996; 55: 735.
  • 19
    Singh G, Athreya B, Fries JF, Goldsmith DP. Measurement of health status in children with juvenile rheumatoid arthritis. Arthritis Rheum 1994; 37: 17619.
  • 20
    Ruperto N, Ravelli A, Pistorio A, Malattia C, Cavuto S, Gado-West L, et al. Cross-cultural adaptation and psychometric evaluation of the Childhood Health Assessment Questionnaire (CHAQ) and the Child Health Questionnaire (CHQ) in 32 countries: review of the general methodology. Clin Exp Rheumatol 2001; 19: S19.
  • 21
    Ravelli A, Viola S, Ruperto N, Corsi B, Ballardini G, Martini A. Correlation between conventional disease activity measures in juvenile chronic arthritis. Ann Rheum Dis 1997; 56: 197200.
  • 22
    Landgraf JM, Abetz L, Ware JE. The CHQ user's manual. 1st ed. Boston: The Health Institute, New England Medical Center; 1996.
  • 23
    Moher D, Schulz KF, Altman DG, for the CONSORT group. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet 2001; 357: 11914.
  • 24
    Pocock SJ. Clinical trials: a practical approach. 1st ed. New York: John Wiley & Sons; 1983.
  • 25
    Donner A. Approaches to sample size estimation in the design of clinical trials: a review. Stat Med 1984; 3: 199214.
  • 26
    Betensky RA. Early stopping to accept H(o) based on conditional power: approximations and comparisons. Biometrics 1997; 53: 794806.
  • 27
    Ravelli A, Martini A. Methotrexate in juvenile idiopathic arthritis: answers and questions. J Rheumatol 2000; 27: 18303.
  • 28
    Lovell DJ, Prieur AM, Woo P, Martini A, for the Pediatric Rheumatology International Trials Organization. Results of a survey of pediatric rheumatologists in North America and Europe concerning therapeutic trials in pediatric rheumatology [abstract]. Arthritis Rheum 1996; 39 Suppl 9: S236.
  • 29
    Edelman J, Biggs DF, Jamali F, Russell AS. Low-dose methotrexate kinetics in arthritis. Clin Pharmacol Ther 1984; 35: 3826.
  • 30
    Brooks P, Spruill W, Parish R, Birchmore D. Pharmacokinetics of methotrexate administered by intramuscular and subcutaneous injections in patients with rheumatoid arthritis. Arthritis Rheum 1990; 33: 914.
  • 31
    Jundt JW, Browne BA, Fiocco GP, Steele AD, Mock D. A comparison of low dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing. J Rheumatol 1993; 20: 18459.
  • 32
    Ravelli A, Gerloni V, Corona F, Falcini F, Lepore L, De Sanctis R, et al. Oral versus intramuscular methotrexate in juvenile chronic arthritis. Clin Exp Rheumatol 1998; 16: 1813.
  • 33
    Wallace CA, Sherry DD. A practical approach to avoidance of methotrexate toxicity. J Rheumatol 1995; 22: 100912.
  • 34
    Freeman-Narrod M, Gerstley BJ, Engstrom PF, Bornstein RS. Comparison of serum concentrations of methotrexate after various routes of administration. Cancer 1975; 36: 161924.
  • 35
    Pearson AD, Mills S, Amineddine HA, Long DR, Craft AW, Chessells JM. Pharmacokinetics of oral and intramuscular methotrexate in children with acute lymphoblastic leukaemia. Cancer Chemother Pharmacol 1987; 20: 2437.
  • 36
    Petri M, Jones RJ, Brodsky RA. High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus. Arthritis Rheum 2003; 48: 16673.
  • 37
    Lambert CM, Sandhu S, Lochhead A, Hurst NP, McRorie E, Dhillon V. Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate: a randomized, controlled trial. Arthritis Rheum 2004; 50: 36471.